Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Melanoma 3Colitis, Ulcerative 3Inflammatory Bowel Diseases 2Crohn Disease 2Pancreatic Neoplasms 1Lymphoma 1Lung Neoplasms 1Hepatitis 1Graft vs Host Disease 1Colitis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Bronchiolitis Obliterans Syndrome 1Arthritis, Rheumatoid 1Anorexia 1Anemia 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × Infliximab × Clear all
NCT00060502 2011-05-17

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Centocor, Inc.

Phase 2 Completed
73 enrolled
Classical hematologyGastrointestinal

Anemia, Anorexia, Cachexia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡